Skip to main content

Compaction ratio for diagnosis of LVNC



Compaction ratio for diagnosis of LVNC

Compaction ratio for diagnosis of LVNC.

Epicardium- to- trabecular- trough thickness is termed compacted myocardium (C), and trabecular- peak- to- trough thickness is termed non- compacted myocardium (NC).


LVNC is considered when NC/ C is greater than 2 by echocardiography and 2.3 by magnetic resonance imaging.


Compaction Ratio for Diagnosis of Left Ventricular Non-Compaction (LVNC)


Overview

Left Ventricular Non-Compaction (LVNC) cardiomyopathy is a structural myocardial disorder characterized by a two-layered left ventricular (LV) wall consisting of a thin, compacted (C) epicardial layer and an abnormally thickened non-compacted (NC) trabecular layer with deep recesses communicating with the LV cavity. LVNC is considered a genetic or primary cardiomyopathy, though increased trabeculation alone may also be seen in healthy individuals, athletes, or pregnancy, making accurate diagnosis essential. 


Compaction Ratio Criteria

The main imaging modalities used to assess LVNC are transthoracic echocardiography (TTE) and cardiac magnetic resonance imaging (CMR). A central quantitative diagnostic parameter across many criteria is the ratio of non-compacted (NC) to compacted (C) myocardial layer thickness (NC:C), typically measured in specific views and phases of the cardiac cycle. 


1. Petersen’s CMR Criterion


NC:C ratio > 2.3 at end-diastole on CMR is one of the most widely cited and validated cut-offs for diagnosing LVNC. This diastolic measurement distinguishes pathological non-compaction from normal trabeculation with high specificity and sensitivity. 



2. Jenni’s Echocardiographic Criterion


On echocardiography, some criteria (e.g., Jenni et al.) define LVNC by a NC:C ratio > 2.0 measured at end-systole in the parasternal short-axis view. 



3. Alternate Imaging Thresholds and Modalities


Computed tomography criteria have proposed a NC:C ratio ≥ 1.8 at end-diastole as discriminating LVNC from normal hearts. 


Some refined CMR approaches also consider segmental thresholds, where a NC:C ≥ 3:1 in non-apical segments offers excellent sensitivity and specificity when combined with other measurements like trabeculated LV mass. 



Why Timing and Modality Matter

Measurements are phase-dependent:


CMR Petersen’s criteria use diastolic images for optimal layer delineation. 


Echocardiographic ratios are more often reported in end-systole to improve layer distinction. 



Strengths and Limitations of NC:C Ratio

The NC:C ratio is simple and quantitative, but has limitations:


Marked trabeculation can be found in individuals without cardiomyopathy, especially athletes and some ethnic groups. 


Different imaging modalities and measurement standards yield varying cut-offs, so correlation with clinical and functional findings remains important. 



Summary of Typical Cut-Offs


Modality Measurement Phase NC:C Diagnostic Threshold


CMR (Petersen) End-diastole >2.3:1 

Echocardiography (Jenni) End-systole >2:1 

CT (Low-dose) End-diastole ≥1.8:1 

CMR Segmental criteria End-diastole ≥3:1 in specified segments 



Conclusion

The NC:C compaction ratio remains a pivotal quantitative tool in diagnosing LVNC, with typical thresholds of >2.3 in diastole by CMR and >2 in systole by echocardiography forming the basis of many established diagnostic criteria. However, interpretation should be integrated with clinical context and other imaging findings due to overlapping features with normal variants and other cardiomyopathies. 

Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.